<DOC>
	<DOCNO>NCT00824265</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ofatumumab add fludarabine-cyclophosphamide patient relapse Chronic Lymphocytic Leukemia ( CLL ) .</brief_summary>
	<brief_title>Ofatumumab Added Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination Relapsed Subjects With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Fludarabine currently approve treatment relapse Chronic Lymphocytic Leukemia . Studies show drug combination fludarabine show effectiveness fludarabine alone . The addition ofatumumab fludarabine-cyclophosphamide combination offer potentially effective therapy , without additional toxicity . The objective study determine effect ofatumumab add fludarabine cyclophosphamide patient Chronic Lymphocytic Leukemia respond previously therapy later develop progressive disease require additional therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>confirm active CLL require treatment least one previous treatment CLL achieve complete partial remission/response period 6 month , show evidence disease progression fully active minimum fully capable selfcare 50 % waking hour age 18yrs older sign write informed consent diagnosis refractory CLL ( failure achieve complete partial remission/response disease progression within 6 month last antiCLL treatment abnormal/inadequate blood value , liver kidney function certain heart problem , serious significant disease , AIHA , current cancer within last 5 year active chronic infection use drug suppress allergic inflammatory response ( glucocorticoid ) CLL transformation CLL central nervous system involvement current participation clinical study inability comply protocol activity lactate pregnant woman female patient childbearing potential ( male patient partner ) willing use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Oncology</keyword>
	<keyword>Safety</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Efficacy</keyword>
</DOC>